Update to fin 0.25 mg, 4x/week Progress Pictures 6/24/2023
User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Androgenetic alopecia is a skin disease: DHT-mediated skin disorders
Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.
community Testosterone and Androgenetic Alopecia
How androgens, including testosterone, can cause hair follicles to miniaturize in people with sensitivity to androgens, and treatments such as finasteride, dutasteride, minoxidil, RU58841, or fluridil may be used in combination for long-term treatment.
community My history with androgenetic alopecia, experience with treatments, side effects, current treatment, etc
User discussed hair loss treatments like Minoxidil, Finasteride, RU58841, and microneedling. They talked about side effects, effectiveness, and their current plan using low-dosage Finasteride and Dutasteride.
community Early Signs - Notes for diffuse thinners
Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.
community Why some people experience problems on Finasteride/Dutasteride (my theory)
Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.
community If we lose hair because of our sensitivity to DHT, then why are we trying to reduce DHT when our sensitive androgen receptors are the culprit?
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
Related Research
6 / 6 results
research Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Potential targets in the discovery of new hair growth promoters for androgenic alopecia
This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
research ANDROGENIC ALOPECIA: PATHOGENETIC MECHANISMS AND THERAPEUTIC APPROACHES
This review discusses treatments for androgenic alopecia, noting that current options like finasteride and minoxidil are effective for only 10% of patients, thus highlighting the need for new therapies.
research Steroid Hormones
This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.
research Pharmacological Options for Treatment of Hyperandrogenic Disorders
This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.